Characterization of high‐affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC‐3 and DU‐145: Internalization of receptor bound 125I‐(Tyr4) bombesin by tumor cells
暂无分享,去创建一个
[1] A. Schally,et al. Inhibition of growth of MKN45 human gastric‐carcinoma xenografts in nude mice by treatment with bombesin/gastrin‐releasing‐peptide antagonist (RC‐3095) and somatostatin analogue RC‐160 , 1994, International journal of cancer.
[2] A. Schally,et al. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. , 1994, Acta oncologica.
[3] A. Schally,et al. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. , 1994, Cancer research.
[4] A. Schally,et al. Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice , 1993, International journal of cancer.
[5] A. Schally,et al. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. , 1993, Cancer letters.
[6] P. Vihko,et al. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. , 1993, Cancer research.
[7] P. Sluss,et al. Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines , 1993, The Prostate.
[8] A. Schally,et al. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. , 1992, Journal of the National Cancer Institute.
[9] J. Shimoda. [Effects of bombesin and its antibody on growth of human prostatic carcinoma cell lines]. , 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
[10] A. Gazdar,et al. Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells. , 1992, Cancer research.
[11] G. Chodak,et al. Basic fibroblast growth factor in human prostate cancer cells. , 1992, Cancer research.
[12] A. MacDonald,et al. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. , 1992, British Journal of Cancer.
[13] A. Schally,et al. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. , 1992, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[14] A. Schally,et al. Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160 , 1992, The Prostate.
[15] A. Schally,et al. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. , 1991, Cancer research.
[16] G. Wilding,et al. Effects of Interferon βser and Transforming Growth Factor β on Prostatic Cell Lines , 1991 .
[17] A Chiarodo,et al. National Cancer Institute roundtable on prostate cancer: future research directions. , 1991, Cancer research.
[18] C. Blat,et al. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. , 1991, Growth factors.
[19] D. Rose,et al. Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor‐related polypeptides , 1991, The Prostate.
[20] I. Takenaka,et al. Role of cyclic AMP and polypeptide growth regulators in growth inhibition by interferon in PC‐3 cells , 1991, The Prostate.
[21] S. Narayan,et al. Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro. , 1990, Cancer research.
[22] J. Abita,et al. Characterization, in some human breast cancer cell lines, of gastrin‐releasing peptide‐like receptors which are absent in normal breast epithelial cells , 1990, International journal of cancer.
[23] E. Rozengurt,et al. Bombesin receptor in membranes from Swiss 3T3 cells. Binding characteristics, affinity labelling and modulation by guanine nucleotides. , 1990, The Biochemical journal.
[24] M. Ciomei,et al. Bombesin stimulates growth of human prostatic cancer cells in vitro , 1990, Cancer.
[25] R. Jensen,et al. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. , 1989, The Journal of biological chemistry.
[26] E. Gelmann,et al. Role of transforming growth factor ‐α in human prostate cancer cell growth , 1989 .
[27] T. Moody,et al. Human glioblastoma cell lines have neuropeptide receptors for bombesin/gastrin-releasing peptide. , 1989, Journal of molecular neuroscience : MN.
[28] D. Rose,et al. Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line , 1989, The Prostate.
[29] A. N. Corps,et al. Characterization of the high-affinity receptors on Swiss 3T3 cells which mediate the binding, internalization and degradation of the mitogenic peptide bombesin. , 1988, The Biochemical journal.
[30] A. Schonbrunn,et al. The bombesin receptor is coupled to a guanine nucleotide-binding protein which is insensitive to pertussis and cholera toxins. , 1988, The Journal of biological chemistry.
[31] T. Moody,et al. Identification of the bombesin-receptor on murine and human cells by cross-linking experiments , 1987, Regulatory Peptides.
[32] E. Rozengurt,et al. Internalization and degradation of peptides of the bombesin family in Swiss 3T3 cells occurs without ligand‐induced receptor down‐regulation. , 1987, The EMBO journal.
[33] A. Schally,et al. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[34] G A McPherson,et al. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. , 1985, Journal of pharmacological methods.
[35] E. Rozengurt,et al. High-affinity receptors for peptides of the bombesin family in Swiss 3T3 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Minna,et al. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. , 1985, Life sciences.
[37] A. Schally,et al. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Isaacs. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer , 1984, The Prostate.
[39] A. Schonbrunn,et al. Characterization of bombesin receptors in a rat pituitary cell line. , 1983, The Journal of biological chemistry.
[40] D Rodbard,et al. Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.
[41] I. Pastan,et al. Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. , 1980, The Journal of biological chemistry.
[42] D. Paulson,et al. Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.
[43] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.